A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer

Manabu Kodama, Kiyotaka Oshikawa, Hideyuki Shimizu, Susumu Yoshioka, Masatomo Takahashi, Yoshihiro Izumi, Takeshi Bamba, Chisa Tateishi, Takeshi Tomonaga, Masaki Matsumoto () and Keiichi I. Nakayama ()
Additional contact information
Manabu Kodama: Medical Institute of Bioregulation, Kyushu University
Kiyotaka Oshikawa: Medical Institute of Bioregulation, Kyushu University
Hideyuki Shimizu: Medical Institute of Bioregulation, Kyushu University
Susumu Yoshioka: Medical Institute of Bioregulation, Kyushu University
Masatomo Takahashi: Medical Institute of Bioregulation, Kyushu University
Yoshihiro Izumi: Medical Institute of Bioregulation, Kyushu University
Takeshi Bamba: Medical Institute of Bioregulation, Kyushu University
Chisa Tateishi: Medical Institute of Bioregulation, Kyushu University
Takeshi Tomonaga: National Institute of Biomedical Innovation, Health, and Nutrition
Masaki Matsumoto: Kyushu University
Keiichi I. Nakayama: Medical Institute of Bioregulation, Kyushu University

Nature Communications, 2020, vol. 11, issue 1, 1-16

Abstract: Abstract Glucose metabolism is remodeled in cancer, but the global pattern of cancer-specific metabolic changes remains unclear. Here we show, using the comprehensive measurement of metabolic enzymes by large-scale targeted proteomics, that the metabolism both carbon and nitrogen is altered during the malignant progression of cancer. The fate of glutamine nitrogen is shifted from the anaplerotic pathway into the TCA cycle to nucleotide biosynthesis, with this shift being controlled by glutaminase (GLS1) and phosphoribosyl pyrophosphate amidotransferase (PPAT). Interventions to reduce the PPAT/GLS1 ratio suppresses tumor growth of many types of cancer. A meta-analysis reveals that PPAT shows the strongest correlation with malignancy among all metabolic enzymes, in particular in neuroendocrine cancer including small cell lung cancer (SCLC). PPAT depletion suppresses the growth of SCLC lines. A shift in glutamine fate may thus be required for malignant progression of cancer, with modulation of nitrogen metabolism being a potential approach to SCLC treatment.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-15136-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15136-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-15136-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().